DEFA14A: Tempest Therapeutics, Inc. Sets Date for 2024 Annual Meeting, Outlines Proposals for Stockholder Vote

Tempest Therapeutics, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, with voting open until June 12, 2024, covering director elections, executive compensation, and auditor ratification.

Summary

• Tempest Therapeutics, Inc. is holding its Annual Meeting of Stockholders on June 13, 2024.
• The meeting will be conducted virtually.
• Stockholders can vote on several key proposals.
• These proposals include the election of three directors: Stephen Brady, Michael Raab, and Ronit Simantov.
• Another proposal involves an advisory vote on the compensation of the company's named executive officers.
• The final proposal is to ratify the selection of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
• Stockholders can vote online at www.ProxyVote.com until June 12, 2024, at 11:59 PM ET.
• Proxy materials, including the Notice, Proxy Statement, and Form 10-K, are available online.
• Stockholders can request free paper or email copies of these materials before May 30, 2024.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating a neutral sentiment. It provides necessary information for shareholders to make informed decisions.

Positives

• The company is providing multiple avenues for stockholders to access proxy materials and vote, including online access, phone requests, and email requests.
• The virtual meeting format allows for broader participation from stockholders.

Future Outlook

The document outlines the agenda for the upcoming annual meeting and seeks stockholder approval on key governance matters.

Industry Context

This is a standard proxy statement related to an annual meeting, a routine part of corporate governance for publicly traded companies.

Stakeholder Impact

• Shareholders are directly impacted through their voting rights on key company decisions.
• The outcome of the votes will influence the composition of the board and the selection of the company's auditor.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals by the deadline.
• The company will hold the Annual Meeting on June 13, 2024.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Voting, Directors, Executive Compensation, Auditor, Ernst & Young, Tempest Therapeutics